Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial
Autor(a) principal: | |
---|---|
Data de Publicação: | 2011 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/30374 |
Resumo: | Background: Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with previous cardiovascular disease or diabetes, the use of BP-lowering agents reduces the incidence of major cardiovascular events. In the absence of higher baseline risk, the use of BP agents reduces the incidence of hypertension. The PREVER-prevention trial aims to investigate the efficacy, safety and feasibility of a populationbased intervention to prevent the incidence of hypertension and the development of target-organ damage. Methods: This is a randomized, double-blind, placebo-controlled clinical trial, with participants aged 30 to 70 years, with pre-hypertension. The trial arms will be chlorthalidone 12.5 mg plus amiloride 2.5 mg or identical placebo. The primary outcomes will be the incidence of hypertension, adverse events and development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new sub-clinical atherosclerosis, and sudden death. The study will last 18 months. The sample size was calculated on the basis of an incidence of hypertension of 14% in the control group, a size effect of 40%, power of 85% and P alpha of 5%, resulting in 625 participants per group. The project was approved by the Ethics committee of each participating institution. Discussion: The early use of blood pressure-lowering drugs, particularly diuretics, which act on the main mechanism of blood pressure rising with age, may prevent cardiovascular events and the incidence of hypertension in individuals with hypertension. If this intervention shows to be effective and safe in a populationbased perspective, it could be the basis for an innovative public health program to prevent hypertension in Brazil. |
id |
UFRGS-2_45a2577a4d7ea33705343ae91f672942 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/30374 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Fuchs, Flávio DanniFuchs, Sandra Cristina Pereira CostaMoreira, Leila BeltramiGus, MiguelNobrega, Antonio Claudio Lucas daFigueiredo, Carlos Eduardo Poli deMion Junior, DécioBortolotto, Luiz AparecidoConsolim-Colombo, Fernanda MarcianoNobre, FernandoCoelho, Eduardo BarbosaMartin, Jose Fernando VilelaMoreno Junior, HeitorCesarino, Evandro JoséFranco, Roberto Jorge da SilvaBrandão, Andréa AraujoSousa, Marcos Roberto deRibeiro, Antônio Luiz PinhoJardim, Paulo Cesar Brandao VeigaAfiune Neto, AbrahãoScala, Luiz César NazárioGomes, Marco Antônio MotaChaves, HiltonAlves, João Guilherme BezerraSobral Filho, Dário CelestinoSilva, Ricardo Pereira eFigueiredo Neto, José Albuquerque deIrigoyen, Maria Claudia CostaCastro, IranSteffens, André AvelinoSchlatter, Rosane PaixãoMello, Renato Gorga Bandeira deMosele, FranciscaGhizzoni, FláviaSilva, Otávio Berwanger da2011-07-27T06:00:47Z20111745-6215http://hdl.handle.net/10183/30374000778193Background: Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with previous cardiovascular disease or diabetes, the use of BP-lowering agents reduces the incidence of major cardiovascular events. In the absence of higher baseline risk, the use of BP agents reduces the incidence of hypertension. The PREVER-prevention trial aims to investigate the efficacy, safety and feasibility of a populationbased intervention to prevent the incidence of hypertension and the development of target-organ damage. Methods: This is a randomized, double-blind, placebo-controlled clinical trial, with participants aged 30 to 70 years, with pre-hypertension. The trial arms will be chlorthalidone 12.5 mg plus amiloride 2.5 mg or identical placebo. The primary outcomes will be the incidence of hypertension, adverse events and development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new sub-clinical atherosclerosis, and sudden death. The study will last 18 months. The sample size was calculated on the basis of an incidence of hypertension of 14% in the control group, a size effect of 40%, power of 85% and P alpha of 5%, resulting in 625 participants per group. The project was approved by the Ethics committee of each participating institution. Discussion: The early use of blood pressure-lowering drugs, particularly diuretics, which act on the main mechanism of blood pressure rising with age, may prevent cardiovascular events and the incidence of hypertension in individuals with hypertension. If this intervention shows to be effective and safe in a populationbased perspective, it could be the basis for an innovative public health program to prevent hypertension in Brazil.application/pdfengTrials (Online). London. Vol. 12 (2011), 7 p.Prevenção de doençasPré-hipertensãoHipertensãoPrevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trialEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSORIGINAL000778193.pdf000778193.pdfTexto completo (inglês)application/pdf336084http://www.lume.ufrgs.br/bitstream/10183/30374/1/000778193.pdf525477ab78799896deb4bdfb83df9e54MD51TEXT000778193.pdf.txt000778193.pdf.txtExtracted Texttext/plain28138http://www.lume.ufrgs.br/bitstream/10183/30374/2/000778193.pdf.txt3e7867a5979454f7ed666b9613adf9c7MD52THUMBNAIL000778193.pdf.jpg000778193.pdf.jpgGenerated Thumbnailimage/jpeg1768http://www.lume.ufrgs.br/bitstream/10183/30374/3/000778193.pdf.jpg46c03d15a886a9bfd4470a395b94e06dMD5310183/303742023-06-29 03:29:42.381208oai:www.lume.ufrgs.br:10183/30374Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-06-29T06:29:42Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial |
title |
Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial |
spellingShingle |
Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial Fuchs, Flávio Danni Prevenção de doenças Pré-hipertensão Hipertensão |
title_short |
Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial |
title_full |
Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial |
title_fullStr |
Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial |
title_full_unstemmed |
Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial |
title_sort |
Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial |
author |
Fuchs, Flávio Danni |
author_facet |
Fuchs, Flávio Danni Fuchs, Sandra Cristina Pereira Costa Moreira, Leila Beltrami Gus, Miguel Nobrega, Antonio Claudio Lucas da Figueiredo, Carlos Eduardo Poli de Mion Junior, Décio Bortolotto, Luiz Aparecido Consolim-Colombo, Fernanda Marciano Nobre, Fernando Coelho, Eduardo Barbosa Martin, Jose Fernando Vilela Moreno Junior, Heitor Cesarino, Evandro José Franco, Roberto Jorge da Silva Brandão, Andréa Araujo Sousa, Marcos Roberto de Ribeiro, Antônio Luiz Pinho Jardim, Paulo Cesar Brandao Veiga Afiune Neto, Abrahão Scala, Luiz César Nazário Gomes, Marco Antônio Mota Chaves, Hilton Alves, João Guilherme Bezerra Sobral Filho, Dário Celestino Silva, Ricardo Pereira e Figueiredo Neto, José Albuquerque de Irigoyen, Maria Claudia Costa Castro, Iran Steffens, André Avelino Schlatter, Rosane Paixão Mello, Renato Gorga Bandeira de Mosele, Francisca Ghizzoni, Flávia Silva, Otávio Berwanger da |
author_role |
author |
author2 |
Fuchs, Sandra Cristina Pereira Costa Moreira, Leila Beltrami Gus, Miguel Nobrega, Antonio Claudio Lucas da Figueiredo, Carlos Eduardo Poli de Mion Junior, Décio Bortolotto, Luiz Aparecido Consolim-Colombo, Fernanda Marciano Nobre, Fernando Coelho, Eduardo Barbosa Martin, Jose Fernando Vilela Moreno Junior, Heitor Cesarino, Evandro José Franco, Roberto Jorge da Silva Brandão, Andréa Araujo Sousa, Marcos Roberto de Ribeiro, Antônio Luiz Pinho Jardim, Paulo Cesar Brandao Veiga Afiune Neto, Abrahão Scala, Luiz César Nazário Gomes, Marco Antônio Mota Chaves, Hilton Alves, João Guilherme Bezerra Sobral Filho, Dário Celestino Silva, Ricardo Pereira e Figueiredo Neto, José Albuquerque de Irigoyen, Maria Claudia Costa Castro, Iran Steffens, André Avelino Schlatter, Rosane Paixão Mello, Renato Gorga Bandeira de Mosele, Francisca Ghizzoni, Flávia Silva, Otávio Berwanger da |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Fuchs, Flávio Danni Fuchs, Sandra Cristina Pereira Costa Moreira, Leila Beltrami Gus, Miguel Nobrega, Antonio Claudio Lucas da Figueiredo, Carlos Eduardo Poli de Mion Junior, Décio Bortolotto, Luiz Aparecido Consolim-Colombo, Fernanda Marciano Nobre, Fernando Coelho, Eduardo Barbosa Martin, Jose Fernando Vilela Moreno Junior, Heitor Cesarino, Evandro José Franco, Roberto Jorge da Silva Brandão, Andréa Araujo Sousa, Marcos Roberto de Ribeiro, Antônio Luiz Pinho Jardim, Paulo Cesar Brandao Veiga Afiune Neto, Abrahão Scala, Luiz César Nazário Gomes, Marco Antônio Mota Chaves, Hilton Alves, João Guilherme Bezerra Sobral Filho, Dário Celestino Silva, Ricardo Pereira e Figueiredo Neto, José Albuquerque de Irigoyen, Maria Claudia Costa Castro, Iran Steffens, André Avelino Schlatter, Rosane Paixão Mello, Renato Gorga Bandeira de Mosele, Francisca Ghizzoni, Flávia Silva, Otávio Berwanger da |
dc.subject.por.fl_str_mv |
Prevenção de doenças Pré-hipertensão Hipertensão |
topic |
Prevenção de doenças Pré-hipertensão Hipertensão |
description |
Background: Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with previous cardiovascular disease or diabetes, the use of BP-lowering agents reduces the incidence of major cardiovascular events. In the absence of higher baseline risk, the use of BP agents reduces the incidence of hypertension. The PREVER-prevention trial aims to investigate the efficacy, safety and feasibility of a populationbased intervention to prevent the incidence of hypertension and the development of target-organ damage. Methods: This is a randomized, double-blind, placebo-controlled clinical trial, with participants aged 30 to 70 years, with pre-hypertension. The trial arms will be chlorthalidone 12.5 mg plus amiloride 2.5 mg or identical placebo. The primary outcomes will be the incidence of hypertension, adverse events and development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new sub-clinical atherosclerosis, and sudden death. The study will last 18 months. The sample size was calculated on the basis of an incidence of hypertension of 14% in the control group, a size effect of 40%, power of 85% and P alpha of 5%, resulting in 625 participants per group. The project was approved by the Ethics committee of each participating institution. Discussion: The early use of blood pressure-lowering drugs, particularly diuretics, which act on the main mechanism of blood pressure rising with age, may prevent cardiovascular events and the incidence of hypertension in individuals with hypertension. If this intervention shows to be effective and safe in a populationbased perspective, it could be the basis for an innovative public health program to prevent hypertension in Brazil. |
publishDate |
2011 |
dc.date.accessioned.fl_str_mv |
2011-07-27T06:00:47Z |
dc.date.issued.fl_str_mv |
2011 |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/30374 |
dc.identifier.issn.pt_BR.fl_str_mv |
1745-6215 |
dc.identifier.nrb.pt_BR.fl_str_mv |
000778193 |
identifier_str_mv |
1745-6215 000778193 |
url |
http://hdl.handle.net/10183/30374 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Trials (Online). London. Vol. 12 (2011), 7 p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/30374/1/000778193.pdf http://www.lume.ufrgs.br/bitstream/10183/30374/2/000778193.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/30374/3/000778193.pdf.jpg |
bitstream.checksum.fl_str_mv |
525477ab78799896deb4bdfb83df9e54 3e7867a5979454f7ed666b9613adf9c7 46c03d15a886a9bfd4470a395b94e06d |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1815447426415198208 |